Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797022 | 1.00 | CHRM3 (0.52) | CHRM3CHRNB2CHRNA4CHRNA5CHRNA7 | |
| SCHEMBL17840987 | 0.92 | CHRM3 (0.54) | CHRM3CHRNB2CHRNA4CHRNA5CHRNA7 | |
| SCHEMBL17840986 | 0.92 | CHRM3 (0.54) | CHRM3CHRNB2CHRNA4CHRNA5CHRNA7 | |
| SCHEMBL17840164 | 0.92 | CHRM3 (0.54) | CHRM3 | |
| SCHEMBL17840162 | 0.92 | CHRM3 (0.54) | CHRM3 | |
| SCHEMBL17840337 | 0.90 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL17840312 | 0.90 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL17839984 | 0.90 | CHRM3 (0.56) | CHRM3CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17840310 | 0.90 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL17839983 | 0.90 | CHRM3 (0.56) | CHRM3CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | claimed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | claimed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | claimed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | claimed |
| EP-4688739-A1 | NOVEL PYRROLIDINIUM COMPOUNDS HAVING ANTAGONISTIC ACTIVITY AGAINST MUSCARINIC RECEPTORS AND USE THEREOF | eFlask Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024205157-A1 | NOVEL PYRROLIDINIUM COMPOUNDS HAVING ANTAGONISTIC ACTIVITY AGAINST MUSCARINIC RECEPTORS AND USE THEREOF | EFLASK CO., LTD. (KR) | 2024-10-03 | — | — | WO | disclosed |
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | disclosed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | CHRM2, CHRM3, CHRM5 | CHRM3 2/4885CHRNB2 38/4885CHRNA4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.